accessibilityalertarrow-downarrow-leftarrow-rightarrow-upchevron-downchevron-leftchevron-rightchevron-upclosedigital-transformationdiversitydownloaddrivedropboxeventsexpandfacebookguideinstagramjob-pontingslanguage-selectorlinkedinlocationmailmenuminuspencilphonephotoplayplussearchsharesoundshottransactionstwitteruploadwebinarwt-arrowyoutube
Press Release Press Release

Wolf Theiss has advised CELLINK AB on a $68 million acquisition of in-vitro tech corporation

MatTek Corporation, a Boston-area life sciences company specialising in lab-engineered human tissue production, has recently been acquired by CELLINK, a leader in bioprinting, multi-omics, cell line development and diagnostics.

For nearly 30 years, MatTek has been a global leader in the production of lab-grown human tissue models used for testing pharmaceuticals, cosmetic and personal care products as more physiologically relevant alternatives to animal testing. With the largest portfolio of proprietary 3D human-derived tissue and disease models in the world, MatTek’s tissues are used in product development and regulatory testing across North America, Europe, and Asia.

Wolf Theiss acted as one of the legal advisors to CELLINK in connection with the acquisition of all outstanding equity interests of MatTek Corporation in Slovakia. The Slovak team included Bruno Štefánik (Counsel, Bratislava), Zuzana Hodoňová (Counsel, Bratislava), Dalibor Palatický (Associate, Bratislava) and Jozef Virčík (Associate, Bratislava).

The acquisition offers market-leading alternative in-vitro methods and replaces animal testing by providing alternative test models. These solutions allow researchers to gather better data through more physiologically relevant models and therefore to make better predictions. Additionally, providing alternative testing models, enables the reduction, and in some cases the elimination, of animal testing.

As a result of the successful transaction, Cellink praised Wolf Theiss for providing excellent counsel and legal services.

CELLINK AB is the leading bioconvergence company in world that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical and cosmetic industries.

Read the full text

Download PDF

Contributors